Hostname: page-component-7c8c6479df-24hb2 Total loading time: 0 Render date: 2024-03-28T08:30:47.680Z Has data issue: false hasContentIssue false

Brain morphology in antipsychotic-naïve schizophrenia: A study of multiple brain structures

Published online by Cambridge University Press:  02 January 2018

W. Cahn*
Affiliation:
Department of Psychiatry, University Medical Centre Utrecht, The Netherlands
H. E. Hulshoff Pol
Affiliation:
Department of Psychiatry, University Medical Centre Utrecht, The Netherlands
M. Bongers
Affiliation:
Department of Psychiatry, University Medical Centre Utrecht, The Netherlands
H. G. Schnack
Affiliation:
Department of Psychiatry, University Medical Centre Utrecht, The Netherlands
R. C. W. Mandl
Affiliation:
Department of Psychiatry, University Medical Centre Utrecht, The Netherlands
N. E. M. Van Haren
Affiliation:
Department of Psychiatry, University Medical Centre Utrecht, The Netherlands
S. Durston
Affiliation:
Department of Psychiatry, University Medical Centre Utrecht, The Netherlands
H. Koning
Affiliation:
Department of Psychiatry, University Medical Centre Utrecht, The Netherlands
J. A. Van Der Linden
Affiliation:
Department of Psychiatry, University Medical Centre Utrecht, The Netherlands
R. S. Kahn
Affiliation:
Department of Psychiatry, University Medical Centre Utrecht, The Netherlands
*
Dr W. Cahn, Department of Psychiatry, University Medical Centre Utrecht, Heidelberglaan 100, 3584 CX Utrecht, The Netherlands. Tel: +31 30 250 8180; fax: +31 30 250 5443; e-mail: w.cahn@azu.nl
Rights & Permissions [Opens in a new window]

Abstract

Background

Although brain volume changes are found in schizophrenia, only a limited number of structural magnetic resonance imaging studies have exclusively examined antipsychotic-naïve patients.

Aims

To comprehensively investigate multiple brain structures in a single sample of patients who were antipsychotic-naïve.

Method

Twenty antipsychotic-naïve patients with first-episode schizophrenia and 20 healthy comparison subjects were included. Intracranial, total brain, frontal lobe, grey and white matter, cerebellar, hippocampal, parahippocampal, thalamic, caudate nucleus and lateral and third ventricular volumes were measured. Repeated-measures analyses of (co)variance were conducted with intracranial volume as covariate.

Results

Third ventricle volume enlargement was found in patients compared with the healthy subjects. No differences were found in other brain regions.

Conclusions

These findings suggest that some brain abnormalities are present in the early stages of schizophrenia. Moreover, it suggests that brain abnormalities reported in patients with chronic schizophrenia develop in a later stage of the disease and/or are medication induced.

Type
Papers
Copyright
Copyright © Royal College of Psychiatrists, 2002 

Numerous imaging studies have reported morphological brain abnormalities in schizophrenia, including studies in first-episode schizophrenia (for reviews see Reference McCarley, Wible and FruminMcCarley et al, 1999; Reference Wright, Rabe-Hesketh and BullmoreWright et al, 2000). However, it is difficult to establish whether these structural brain abnormalities are caused by the disease or are from the effects of treatment. Imaging studies in patients with schizophrenia who have never been exposed to antipsychotic medication may help to clarify whether brain changes are already present in an early stage of the disease and are independent of medication use. This current study examined multiple brain structures in a single sample of antipsychotic-naïve patients with schizophrenia compared with a sample of carefully matched healthy comparison subjects. Intracranial volume, total brain, grey and white matter of the cerebrum, frontal lobe, cerebellar, hippocampal, parahippocampal, thalamic, caudate nucleus and lateral and third ventricular volumes were assessed.

As evidence is accumulating that medication may alter brain structures (increases in basal ganglia volumes have been related to antipsychotic intake (Reference Chakos, Lieberman and BilderChakos et al, 1994; Reference Keshavan, Bagwell and HaasKeshavan et al, 1994; Reference Scheepers, de Wied and PolScheepers et al, 2001) and decreases in frontal lobe volume have been related to the amount of antipsychotic medication used (Reference Gur, Cowell and TuretskyGur et al, 1998a ; Reference Madsen, Keidling and KarleMadsen et al, 1998)), the study of brain morphology in antipsychotic-naïve patients with schizophrenia is crucial for an understanding of the disease. Studies comparing antipsychotic-naïve patients with first-episode schizophrenia with healthy comparison subjects have examined only one or a few brain structures (Table 1). These studies have inconsistently reported brain volume changes in antipsychotic-naïve patients with schizophrenia compared with healthy volunteers, which could be caused by factors such as a large variation in scanning acquisition and volumetric measures, inclusion of small numbers of subjects, inclusion of patients with a diagnosis other than schizophrenia and failure to match for age, gender, socio-economic class or handedness. In addition, some studies were not designed to exclusively compare antipsychotic-naïve patients with healthy comparison subjects.

Table 1 Review of magnetic resonance imaging (MRI) literature in antipsychotic-naïve patients with schizophrenia

Author Subjects Brain regions examined Matching MRI Results Comment
Reference Buchsbaum, Someya and TengBuchsbaum et al, 1996 20 m-sz Thalamus Not clearly matched 7.5-mm slices No volume differences Primarily PET study
15 nc
Reference Keshavan, Rosenberg and SweeneyKeshavan et al, 1998a 16 m-sz Cranium, caudate, putamen Age, gender, parental education and own education 1.5 T Left caudate reduced in both patient groups
9 non sz 2.8-mm slices
17 nc
Reference Keshavan, Haas and KahnKeshavan et al, 1998b 17 m-sz Cranium, STG, cerebellum Not clearly matched 1.5 T Smaller left STG After 1 year follow-up repeat MRI showed reduced total STG
8 non sz 5-mm slices
17 nc 1-mm gap
Reference Gur, Cowell and TuretskyGur et al, 1998a 1 20 m-sz Total brain, CSF, frontal lobe, temporal lobe Not clearly matched 1.5 T Reduced total brain, frontal and temporal lobes. CSF no difference Designed as a follow-up study
20 prev. treat. sz 5-mm slices
17 nc
Reference Gur, Maany and MozleyGur et al, 1998b 21 m-sz Cranium, caudate, putamen, globus pallidus, thalamus, total brain, CSF, ventricles Age, parental education, handedness 1.5 T Thalamic volume reduction trend. Total brain, CSF, ventricles, globus pallidus, putamen no difference Increased subcortical volumes related to amount of antipsychotics
75 prev. treat. sz 1-mm slices
128 nc
Reference Shihabuddin, Buchsbaum and HazlettShihabuddin et al, 1998 7 m-sz Caudate, putamen Age, gender 1.2-mm slices Smaller caudate and putamen Primarily PET study
11 drug-free sz
24 nc
Westmoreland et al, 1999 36 m-sz Cranium, grey and white matter, caudate, CSF Age, gender, socio-economic status 1.5 T Smaller caudate. Differences of cranium, grey and white matter and CSF not reported Corrected for intracranial volume (calculated by adding grey, white matter and CSF)
43 nc 1.5-mm slices
Reference Gur, Turetsky and CowellGur et al, 2000a 1 39 m-sz Hippocampus, amygdala, STG, temporal pole Parental education 1.5 T Smaller hippocampus, STG and temporal pole. Amygdala no difference
61 prev. treat. sz 1-mm slices
110 nc
Reference Gur, Cowell and LatshawGur et al, 2000b 1 29 m-sz Prefrontal white and grey matter (orbital and dorsal regions) Parental education 1.5 T Reduced prefrontal grey matter
41 prev. treat. sz 1-mm slices
81 nc
Reference Laakso, Tiihonen and SyvalahtiLaakso et al, 2001 18 m-sz Hippocampus Age, gender, handedness, parental socio-economic status 1.5 T No difference in hippocampal volume
22 nc 1.5-mm slices
Reference Ichimiya, Okubo and SuharaIchimiya et al, 2001 20 m-sz Cranium, cerebrum, cerebellar grey and white, vermis Age?, handedness 1.5 T Reduced cerebellar vermis. Total cerebellum, cranium and cerebrum no difference
20 nc 2-mm slices

METHOD

Subjects

Twenty patients in their first psychotic episode of schizophrenia were recruited from the First-Episode Schizophrenia Research programme at the University Medical Centre Utrecht. Patients had not received antipsychotic treatment prior to scanning. All patients met DSM—IV (American Psychiatric Association, 1994) criteria for schizophrenia (11 paranoid, 8 undifferentiated, 1 disorganised type), on the basis of the Comprehensive Assessment of Symptoms and History (CASH; Reference Andreasen and ArndtAndreasen & Arndt, 1992) rated by two independent raters. Nineteen patients (one patient was lost to follow-up) had the diagnosis confirmed after 1 year. The start of prodromal symptoms and psychotic illness was measured by a shortened version of the Interview for the Retrospective Assessment of the Onset of Schizophrenia (IRAOS; Reference Häfner, Riecher-Rossler and HambrechtHäfner et al, 1992). Severity of illness was measured with the Positive and Negative Symptom Scale (PANSS; Reference Kay, Fiszbein and OplerKay et al, 1987). Twenty healthy comparison subjects were recruited and carefully matched for gender, age, parental education and handedness. They were all screened with the Schedule for Affective Disorders and Schizophrenia — Lifetime Version (SADS—L; Reference Endicott and SpitzerEndicott & Spitzer, 1978) and fulfilled criteria for ‘never mentally ill’. All subjects were physically healthy (except one patient who had congenital hypothyroidism, but was stable on supplementation medication), had neither a history of head injury nor a diagnosis of drug or alcohol misuse or dependence. All patients and healthy comparison subjects provided written informed consent to participate in the study. For demographic and clinical data see Table 2.

Table 2 Demographic and clinical data for antipsychotic-naïve patients with schizophrenia and healthy comparison subjects

Patients (n=20) Controls (n=20) t or χ2 P
Gender, n
Male 16 16 χ2=0.00 1.00
Female 4 4
Handedness, n
Right 18 18 χ2=0.00 1.00
Left 2 2
Age, years (mean (s.d.)) 27.63 (6.43) 27.24 (6.30) t=0.20 0.85
Weight, kg (mean (s.d.)) 75.50 (14.64) 77.05 (11.68) t=0.37 0.72
Height, cm (mean (s.d.)) 175.45 (9.43) 184.68 (7.94) t=3.30 0.002*
Parental education level, years (mean (s.d.)) 12.3 (3.8) 14.1 (2.7) t=1.18 0.11
Education, years (mean (s.d.)) 11.6 (3.0) 12.7 (3.0) t=1.67 0.25
Subtype of schizophrenia according to DSM-IV, n
Paranoid 11
Disorganised 1
Undifferentiated 8
Prodromal phase, months (mean (s.d.)) 48.1 (61.1)
Psychosis, months (mean (s.d.)) 17.5 (27.2)
PANSS positive symptoms (mean (s.d.)) 21.1 (5.1)
PANSS negative symptoms (mean (s.d.)) 21.3 (6.3)
PANSS psychopathology (mean (s.d.)) 38.0 (11.1)

Brain imaging

MRI acquisition

Magnetic resonance images (MRIs) were acquired on a Philips NT scanner operating at 1.5 T. A T1-weighted three-dimensional fast field echo (3D-FFE: echo time (TE)=4.6 ms, repetition time (TR)=30 ms, flip angle=30°, field of view (FOV)=256/80% mm) with 160-180 contiguous coronal 1.2-mm slices, and a T2-weighted dual echo turbo spin-echo (DTSE: TE1=14 ms, TE2=80 ms, TR=6350 ms, flip angle=90°, FOV=256/80% mm) with 120 contiguous coronal 1.6-mm slices of the whole head were used for the quantitative measurements. In addition, a T2-weighted DTSE (TE1=9 ms, TE2=100 ms, TR=2200 ms, flip angle=90°, FOV=250/100% mm) with 17 axial 5-mm slices and 1.2-mm gap of the whole head was acquired for clinical neurodiagnostic evaluation. Processing was carried out on the neuroimaging computer network of the Department of Psychiatry. Before quantitative assessments, 10 images were randomly chosen and cloned for interrater reliability purposes determined by the intraclass correlation coefficient (ICC). All images were coded to ensure blindness for subject identification and diagnosis, scans were entered into Talairach frame (no scaling) (Reference Talairach and TournouxTalairach & Tournoux, 1988) and corrected for inhomogeneities in the magnetic field (Reference Sled, Zijdenbos and EvansSled et al, 1998).

Volume measurements

Intracranial, total brain, cerebral grey and white matter, lateral ventricles and third ventricle and cerebellar volumes were measured automatically by using histogram analysis algorithms and series of mathematical morphological operators to connect all voxels of interest (Schnack et al, Reference Schnack, Hulshoff Pol and Baaré2001a ,Reference Schnack, Hulshoff Pol and Baaré b ). Intracranial volume was segmented on the DTSE scans, with the foramen magnum being used as inferior boundary. Total brain volumes were segmented on the 3D-FEE (T1-weighted) scans and contained grey and white matter tissue only. In lateral ventricle segmentation automatic decision rules bridged connections not detectable and prevented ‘leaking’ into cisterns. The third ventricle was limited by coronal slices, clearly showing the anterior and posterior commissures; the upper boundary was a plane through the plexus choroideus ventriculi tertii in the midsagittal slice perpendicular to this slice. The cerebellum was limited by the tentorium cerebelli and the brain-stem. All images were checked after the measurements and corrected manually if necessary. The inter-rater reliability of the measurements determined by the ICC based on 10 brains was 0.95 and higher. Segmentation of the frontal lobe was performed automatically using the ANIMAL anatomical segmentation algorithm (Reference Collins, Neelin and PetersCollins et al, 1994), which was validated previously for frontal lobe volume measurements (Reference Mandl, Hulshoff Pol and CollinsMandl et al, 1999).

Quantitative measurements of the caudate nucleus, thalamus, hippocampus and parahippocampus were obtained manually, from the 3D-FFE image using Analyze™ (Reference RobbRobb, 1995). The caudate nucleus was anteriorly defined in the first slice in which it was clearly visible. Its medial border was the lateral ventricle. Laterally, it was limited by the internal capsule, excluding the interconnecting grey matter striae between caudate and putamen visible in the internal capsule; posteriorly, by the last slice before the one in which the posterior commissure was clearly visible. Its inferior border was defined: anteriorly by the white matter connecting the rostrus corporis callosi and the capsula externa. Then, from the first slice where the putamen is clearly visible until the slice anterior to the slice in which the anterior commissure crosses the midline, the nucleus accumbens was separated by a line from the most inferior point of the lateral ventricle to the most inferior point of the internal capsule (adapted from Reference Chakos, Lieberman and BilderChakos et al, 1994). The thalamus was anteriorly defined in the first slice in which it was clearly visible, and precisely demarcated in the subsequent slices until the first slice after the coronal slice that included the posterior commissure. Its lateral border was defined by the internal capsule; its medial border by the third ventricle and its inferior boundary was defined by the anterior commissure—posterior commissure plane. Segmentation of the hippocampus was started in the coronal slice in which the mammaillary bodies were visible and stopped when the fornix was visible as a continuous tract (adapted from Reference Watson, Andermann and GloorWatson et al, 1992). Parahippocampal gyrus segmentation began in the coronal slice in which the optic tract is situated above the amygdala. The posterior commissure was its posterior border. Single operators performed the volume measurements of the above-named structures. The ICC for the left and right caudate nucleus was 0.98 and 0.99, for the thalamus, 0.77 and 0.86, for the hippocampus, 0.81 and 0.80 and for the parahippocampal gyrus, 0.77 and 0.75.

Statistical analyses

Repeated-measures analysis of covariance was conducted for total brain, grey and white matter of the cerebrum (total brain, excluding cerebellum and brainstem), frontal lobe, cerebellum, hippocampus, parahippocampus, thalamus, caudate volumes and ventricles, with group (patients, healthy comparison subjects) as the between-subjects variable and, if applicable, side (left, right) and matter (grey, white) as the within-subjects variable. Intracranial brain volume served as covariate for total brain, grey and white matter of the cerebrum, cerebellar, lateral and third ventricle volume measures. Total brain volume served as covariant for frontal lobe, hippocampal, parahippocampal, thalamic and caudate volumes.

To examine associations between significant brain volume differences and clinical variables (prodromal phase, duration of untreated psychosis, PANSS scores) Pearson's correlations were calculated with intracranial volume as a covariate. To assess the power of the study a power analysis, uncorrected for intracranial volume, was carried out with a probability of 0.7 at an α level of 0.05.

RESULTS

As seen in Table 2, patients and healthy comparison subjects did not significantly differ for gender, handedness, age, weight and parental education. Although not matched for education, patients did not differ from healthy comparison subjects on years of education. Patients and healthy comparison subjects did significantly differ in height, but as intracranial volume was used as covariate, the results presented below are uncontrolled for height. However, results did not change when height was used as a covariate.

Mean (s.d.) volumes of total brain, frontal brain, grey matter, white matter, cerebellum, hippocampus, parahippocampus, thalamus, caudate nucleus, lateral ventricles and third ventricle are presented in Table 3 for patients and healthy comparison subjects.

Table 3 Volumes (cm3) of brain regions in antipsychotic-naïve patients with schizophrenia and comparison subjects

Region Patients with schizophrenia (n=20) Comparison subjects (n=20) Effect size Observed power
Cranium 1463.25 (130.71) 1538.87 (164.37) 0.06 0.35
Total brain 1281.57 (118.70) 1353.94 (138.96) 0.08 0.41
Grey matter 669.87 (58.66) 691.93 (54.92) 0.04 0.22
White matter 455.19 (66.27) 499.47 (90.85) 0.08 0.40
Frontal lobe 280.99 (30.69) 299.64 (32.39) 0.08 0.45
Cerebellum 142.78 (14.71) 148.52 (13.03) 0.04 0.25
Caudate 9.22 (1.08) 9.19 (1.24) 0.00 0.05
Thalamus 14.37 (1.31) 14.97 (2.09) 0.03 0.18
Hippocampus 8.01 (0.77) 8.36 (0.80) 0.05 0.28
Parahippocampus 4.93 (0.94) 5.63 (1.14) 0.11 0.55
Lateral ventricles 13.18 (6.90) 14.82 (12.21) 0.01 0.08
Third ventricle* 0.85 (0.32) 0.62 (0.36) 0.11 0.54

Intracranial volume and total brain measures

Intracranial volume (F=2.59, d.f.=1,38, P=0.12), total brain volume (F=0.55, d.f.=1,37, P=0.47) and cerebral volume (F=0.36, d.f.=1,37, P=0.56) did not differ significantly between the two groups, nor was there a significant interaction effect of group with matter (grey, white) of the cerebrum (F=0.21, d.f.=1,38, P=0.65).

Frontal lobe and cerebellum

Frontal lobe volume (F=0.34, d.f.=1,37, P=0.56) and cerebellar volume (F=0.34, d.f.=1,37, P=0.57) did not differ significantly between the two groups.

Hippocampus, parahippocampus, thalamus and caudate nucleus

Hippocampus (F=0.11, d.f.=1,37, P=0.74), parahippocampus (F=2.05, d.f.=1,37, P=0.16), thalamus (F=0.28, d.f.=1,37, P=0.60), and caudate nucleus (F=1.23, d.f.=1,37, P=0.27) did not differ significantly between the two groups.

Ventricles

Lateral ventricle volume (F=0.15, d.f.=1,37, P=0.70) did not significantly differ between the two groups. However, third ventricle volume was significantly larger in patients compared with the comparison subjects (F=8.92, d.f.=1,37, P=0.005) (Fig. 1).

Fig. 1 Third ventricle volume in antipsychotic-naïve patients with first-episode schizophrenia and healthy comparison subjects.—indicates mean third ventricle volume for the patients and controls.

No significant interaction effects of group with matter or with side for any of these measures were found. No correlations were found between third ventricle volume and the clinical data. Excluding the patient with congenital hypothyroidism and her matched comparison subject did not alter the results.

DISCUSSION

This study compared multiple brain structures in a sample of antipsychotic-naïve patients with schizophrenia with those of matched healthy comparison subjects. Volumes of the cranium, total brain, grey and white matter of the cerebrum, frontal lobe, cerebellum, hippocampus, parahippocampus, thalamus, caudate nucleus and lateral and third ventricles were measured. We found third ventricle enlargement in the patients. The other structures were similar in both patients with schizophrenia and healthy comparison subjects.

Third ventricle enlargement in antipsychotic-naïve patients with schizophrenia

To our knowledge, third ventricle volume has not been examined with MRI in patients with schizophrenia who were antipsychotic-naïve. Third ventricle enlargement has been reported in studies of first-episode schizophrenia examining mixed (antipsychotic-naïve and -treated subjects) samples of patients (for review see Reference Fannon, Chitnis and DokuFannon et al, 2000). A possible volume reduction in surrounding diencephalic brain regions could explain the third ventricle enlargement, although in our study this was not expressed in a reduction of thalamic volume. The absence of a reduction in thalamic volume in our study is consistent with the studies performed in anti-psychotic-naïve patients with schizophrenia (Reference Buchsbaum, Someya and TengBuchsbaum et al, 1996; Reference Gur, Maany and MozleyGur et al, 1998b ). Interestingly, third ventricle enlargement but also thalamic volume decrease were found in the healthy siblings of patients with schizophrenia (Staal et al, Reference Staal, Hulshoff Pol and Schnack1998), Reference Staal, Hulshoff Pol and Schnack1999a ; Reference Lawrie, Whalley and KestelmanLawrie et al, 1999; Reference Seidman, Faraone and GoldsteinSeidman et al, 1999), suggesting that these findings could be related to a genetic vulnerability for schizophrenia. The discrepancy of an increase of third ventricle without a corresponding decrease in thalamic volume in this study might be related to the relatively limited number of patients included, or could imply that other regions in the proximity of the third ventricle, such as the hypothalamus, are involved. Abnormalities in the hypothalamic—pituitary—adrenal axis have been suggested to be present in schizophrenia (Reference Tandon, Mazzara, De Quardo and CraigTandon et al, 1991; Reference Jansen, Gispen-de Wied and KahnJansen et al, 2000; Reference Walder, Walker and LewineWalder et al, 2000); however, to date no study has been published measuring the hypothalamus in schizophrenia.

No volume changes in brain tissue

This study found normal total brain and frontal lobe volume in antipsychotic-naïve patients. This finding is inconsistent with the findings by Gur et al Reference Gur, Cowell and Turetsky1998a , Reference Gur, Cowell and Latshaw2000b ), demonstrating total brain and frontal lobe reduction, specifically in prefrontal grey matter, in antipsychotic-naïve patients with schizophrenia. In these studies, however, a mixed sample of antipsychotic-naïve patients and previously treated patients with schizophrenia was examined. Our finding of a normal hippocampus in antipsychotic-naïve patients is congruent with the only other MRI study (Reference Laakso, Tiihonen and SyvalahtiLaakso et al, 2001) designed to examine hippocampal volumes in antipsychotic-naïve patients compared with healthy comparison subjects. Similar caudate nucleus volumes in both antipsychotic-naïve patients and healthy comparison subjects have also been reported in one study (Reference Gur, Maany and MozleyGur et al, 1998b ), but not in others (Reference Keshavan, Rosenberg and SweeneyKeshavan et al, 1998a ; Reference Shihabuddin, Buchsbaum and HazlettShihabuddin et al, 1998; Reference Corson, Nopoulos and AndreasenCorson et al, 1999). The latter studies found reduced volumes in patients. Differences in the various samples, such as diagnosis and handedness, as well as variations in quantitative assessment techniques might explain these inconsistencies.

Relative paucity of brain abnormalities

The relative paucity of brain abnormalities found in this study may actually be the most striking finding. It stands in marked contrast with findings in patients with more chronic schizophrenia, where volume reductions in total brain and medial temporal lobe structures as well as volume enlargement of lateral ventricles have been reported consistently (for review see Reference Wright, Rabe-Hesketh and BullmoreWright et al, 2000). However, the most likely reason for this relative paucity of brain abnormalities is a lack of power, as only 20 patients and 20 healthy comparison subjects were included in this study. Several other explanations, besides the lack of power, can be suggested to explain this discrepancy. First, progression of the illness could lead to an increase of brain abnormalities. A limited number of longitudinal studies in patients with first-episode schizophrenia have been conducted suggesting that brain abnormalities may indeed become more prominent over time (Reference DeLisi, Sakuma and TewDeLisi et al, 1997; Reference Gur, Cowell and TuretskyGur et al, 1998a ) at least in a subgroup of patients with poor outcome (Reference Lieberman, Chakos and WuLieberman et al, 2001). Second, medication might increase brain abnormalities and could contribute to these brain volume changes as suggested by Gur et al (Reference Gur, Cowell and Turetsky1998a ) and Madsen et al (Reference Madsen, Keidling and Karle1998). Third, finding few brain abnormalities in antipsychoticnaïve patients could be the result of a selection bias favouring the inclusion of patients who have a less severe form of schizophrenia. Two characteristics of our sample, high education and a later age of onset, suggest it might indeed not be representative of all patients with first-episode schizophrenia. In our study no difference between patients and healthy comparison subjects on years of education existed. A total of 9 patients of 20 had even completed part or all of university training. In addition, their mean age at onset was at about 27 years. Interestingly, high education and a later age of onset are both related to good outcome (Reference Johnstone, Owens and BydderJohnstone et al, 1989; Weiselgren & Lindstrom, 1996), which in turn appears to be associated with a relative lack of brain abnormalities at presentation of illness (Reference Staal, Abel and Hulshoff PolStaal et al, 1999b ). It has also been suggested that grey matter volume is related to IQ (Reference Andreasen, Flaum and SwayzeAndreasen et al, 1993). Therefore, in this study a level of education (and presumably premorbid IQ) similar in patients to that of the healthy comparison subjects could have resulted in finding no decrements in (regional) grey matter volume. Thus, although the relative paucity of brain volume abnormalities in our sample could be indicative of progressive brain changes in schizophrenia because of illness and/or medication, alternatively it could have been the result of a selection bias that may be hard to avoid when studying antipsychotic-naïve patients with schizophrenia.

Future studies

Although it may be practically impossible to determine whether brain abnormalities in schizophrenia result from the progression of the illness and/or medication, the suggestion of medication having an effect on brain volume changes should be an incentive for future longitudinal studies to carefully monitor medication intake.

CLINICAL IMPLICATIONS

  1. Third ventricle enlargement in antipsychotic-naive first-episode patients with schizophrenia suggests abnormalities in schizophrenia in the diencephalic region of the brain at the onset of the disease.

  2. Antipsychotic medication might be partly implicated for brain abnormalities found in schizophrenia.

  3. The relative paucity of brain abnormalities in patients with first-episode schizophrenia suggests that an underlying neurodegenerative process cannot be excluded.

LIMITATIONS

  1. The study group was relatively small as a result of the inclusion requirements such as no prior antipsychotic use and no illict drug or alcohol misuse/dependence, which is highly prevalent in first-episode schizophrenia.

  2. Although previous education in patients suggested a high (premorbid) IQ, no formal IQ testing was performed.

  3. Patients were carefully matched to the healthy comparison subjects but they did significantly differ in height. However, when height was used as a covariate results did not change.

Footnotes

Presented in part at the European First Episode Schizophrenia Network Meeting, Whistler BC, Canada, 27 April 2001.

Declaration of Interest

None.

References

American Psychiatric Association (1994) Diagnostic and Statistical Manual of Mental Disorders (4th edn) (DSM–IV). Washington, DC: APA.Google Scholar
Andreasen, N. C. & Arndt, S. (1992) The comprehensive assessment of symptoms and history (CASH); An instrument for assessing diagnosis and psychopathology. Archives of General Psychiatry, 49, 615623.Google Scholar
Andreasen, N. C. Flaum, M., Swayze, V., et al (1993) Intelligence and brain structure in normal individuals. American Journal of Psychiatry, 150, 130134.Google ScholarPubMed
Buchsbaum, M. S., Someya, T., Teng, C. Y., et al (1996) PET and MRI of the thalamus in never-medicated patients with schizophrenia. American Journal of Psychiatry, 153, 191199.Google Scholar
Chakos, M. H., Lieberman, J. A., Bilder, R. M., et al (1994) Increase in caudate nuclei volumes of first-episode schizophrenic patients taking antipsychotic drugs. American Journal of Psychiatry, 151, 14301436.Google Scholar
Collins, D. L., Neelin, P., Peters, T. M., et al (1994) Automatic 3D intersubject registration of MR volumetric data in standardized Talairach space. Journal of Computer Assisted Tomography, 18, 192205.CrossRefGoogle ScholarPubMed
Corson, P. W., Nopoulos, P., Andreasen, N. C., et al (1999) Caudate size in first-episode neuroleptic-naïve schizophrenic patients measured using an artificial neural network. Society of Biological Psychiatry, 46, 712720.Google Scholar
DeLisi, L. E., Sakuma, M., Tew, W., et al (1997) Schizophrenia as a chronic active brain process: a study of progressive brain structural change subsequent to the onset of schizophrenia. Psychiatry Research, 74, 129140.Google Scholar
Endicott, J. & Spitzer, R. L. (1978) Diagnostic interview: the Schedule for Affective Disorders and Schizophrenia. Archives of General Psychiatry, 35, 837844.CrossRefGoogle ScholarPubMed
Fannon, D., Chitnis, X., Doku, V., et al (2000) Features of structural brain abnormality detected in first-episode psychosis. American Journal of Psychiatry, 157, 18291832.CrossRefGoogle ScholarPubMed
Gur, R. E., Cowell, P., Turetsky, B. I., et al (1998a) A follow-up magnetic resonance imaging study of schizophrenia. Relationship of neuroanatomical changes to clinical and neurobehavioral measures. Archives of General Psychiatry, 55, 145152.Google Scholar
Gur, R. E., Maany, V., Mozley, P. D., et al (1998b) Subcortical MRI volumes in neuroleptic naive and treated patients with schizophrenia. American Journal of Psychiatry, 155, 17111717.Google Scholar
Gur, R. E., Turetsky, B. I., Cowell, P. E., et al (2000a) Temporolimbic volume reductions in schizophrenia. Archives of General Psychiatry, 57, 769775.CrossRefGoogle ScholarPubMed
Gur, R. E., Cowell, P. E., Latshaw, A., et al (2000b) Reduced dorsal and orbital prefrontal gray matter volumes in schizophrenia. Archives of General Psychiatry, 57, 761768.Google Scholar
Häfner, H., Riecher-Rossler, A., Hambrecht, M., et al (1992) IRAOS: an instrument for the assessment of onset and early course of schizophrenia. Schizophrenia Research, 6, 209223.CrossRefGoogle ScholarPubMed
Ichimiya, T., Okubo, Y., Suhara, T., et al (2001) Reduced volume of the cerebellar vermis in neuroleptic-naïve schizophrenia. Biological Psychiatry, 49, 2027.Google Scholar
Jansen, L. M., Gispen-de Wied, C. C. & Kahn, R. S. (2000) Selective impairments in the stress response in schizophrenic patients. Psychopharmacology, 149, 319325.CrossRefGoogle ScholarPubMed
Johnstone, E. C., Owens, D. G., Bydder, G. M., et al (1989) The spectrum of structural brain changes in schizophrenia: age of onset as a predictor of cognitive and clinical impairment and their cerebral correlates. Psychological Medicine, 19, 91103.Google Scholar
Kay, S. R., Fiszbein, A. & Opler, L. A. (1987) The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophrenia Bulletin, 13, 261276.Google Scholar
Keshavan, M. S., Bagwell, W. W., Haas, G. L., et al (1994) Changes in caudate volume with neuroleptic treatment (letter). Lancet, 353, 1434.Google Scholar
Keshavan, M. S., Rosenberg, D., Sweeney, J. A., et al (1998a) Decreased caudate volume in neuroleptic-naïve psychotic patients. American Journal of Psychiatry, 155, 774778.Google ScholarPubMed
Keshavan, M. S., Haas, G. L., Kahn, C. E., et al (1998b) Superior temporal gyrus and the course of early schizophrenia: progressive, static, or reversible? Journal of Psychiatric Research, 32, 161167.CrossRefGoogle ScholarPubMed
Laakso, M. P., Tiihonen, J., Syvalahti, E., et al (2001) A morphometric MRI study of the hippocampus in first-episode, neuroleptic-naive schizophrenia. Schizophrenia Research, 50, 37.CrossRefGoogle ScholarPubMed
Lawrie, S. M., Whalley, H., Kestelman, J. N., et al (1999) Magnetic resonance imaging of brain in people at high risk of developing schizophrenia. Lancet, 353, 3033.Google Scholar
Lieberman, J., Chakos, M., Wu, H., et al (2001) Longitudinal study of brain morphology in first episode schizophrenia. Biological Psychiatry, 49, 487499.Google Scholar
Madsen, A. L., Keidling, N., Karle, A., et al (1998) Neuroleptics in progressive structural brain abnormalities in psychiatric illness (letter). Lancet, 352, 784785.Google Scholar
Mandl, R. C. W., Hulshoff Pol, H. E., Collins, D. L., et al (1999) Automatic volume measurement in schizophrenia: non linear or linear transformation? (abstract). Neurolmage, 9, S112.Google Scholar
McCarley, R. W., Wible, C. G., Frumin, M., et al (1999) MRI anatomy of schizophrenia. Biological Psychiatry, 45, 10991119.CrossRefGoogle ScholarPubMed
Robb, R. A. (1995) Three-Dimensional Biomedical Imaging – Principles and Practice. New York: VCH Publishers.Google Scholar
Scheepers, F. E., de Wied, C. C., Pol, H. E., et al (2001) The effect of clozapine on caudate nucleus volume in schizophrenic patients previously treated with typical antipsychotics. Neuropsychopharmacology, 24, 4764.Google Scholar
Schnack, H. G., Hulshoff Pol, H. E., Baaré, W. F., et al (2001a) Automated separation of gray and white matter from MR images of the human brain. NeuroImage, 13, 230237.CrossRefGoogle ScholarPubMed
Schnack, H. G., Hulshoff Pol, H. E., Baaré, W. F., et al (2001b) Automatic separation of the ventricular system from MR images of the human brain. NeuroImage, 14, 95104.Google Scholar
Seidman, L. J., Faraone, S. V., Goldstein, J. M., et al (1999) Thalamic and amygdala-hippocampal volume reductions in first-degree relatives of patients with schizophrenia: an MRI-based morphometric analysis. Biological Psychiatry, 46, 941954.CrossRefGoogle ScholarPubMed
Shihabuddin, L., Buchsbaum, M. S., Hazlett, E. A., et al (1998) Dorsal striatal size, shape, and metabolic rate in never-medicated and previously medicated schizophrenics performing a verbal learning task. Archives of General Psychiatry, 55, 235243.CrossRefGoogle ScholarPubMed
Sled, J. G., Zijdenbos, A. P. & Evans, A. C. (1998) A nonparametric method for automatic correction of intensity nonuniformity in MRI data. IEEE Transactions on Medical Imaging, 17, 8797.Google Scholar
Staal, W. G., Hulshoff Pol, H. E., Schnack, H., et al (1998) Partial volume decrease of the thalamus in relatives of patients with schizophrenia. American Journal of Psychiatry, 155, 17841786.Google Scholar
Staal, W. G., Hulshoff Pol, H. E., Schnack, H. G., et al (1999a) Structural brain abnormalities in schizophrenia in relation to genotype (abstract). Schizophrenia Research, 36, 211.Google Scholar
Staal, W. G., Abel, L., Hulshoff Pol, H. E., et al (1999b) Outcome of schizophrenia in relation to brain abnormalities. Schizophrenia Bulletin, 25, 337348.Google Scholar
Tandon, R., Mazzara, C., De Quardo, J., Craig, K. A., et al (1991) Dexamethasone suppression test in schizophrenia: relationship to symptomatology, ventricular enlargement, and outcome. Biological Psychiatry, 29, 953964.CrossRefGoogle ScholarPubMed
Talairach, J. & Tournoux, P. (1988) Co-Planar Stereotaxic Atlas of the Human Brain. 3-Dimensional Propositional System: An Approach to Cerebral Imaging. New York: Thieme.Google Scholar
Walder, D. J., Walker, E. F., Lewine, R. J. (2000) Cognitive functioning, cortisol release, and symptom severity in patients with schizophrenia. Biological Psychiatry, 48, 11211132.Google Scholar
Watson, C., Andermann, R., Gloor, P., et al (1992) Anatomic basis of amygdaloid and hippocampal volume measurement by magnetic resonance imaging. Neurology, 42, 17431750.CrossRefGoogle ScholarPubMed
Wieselgren, I. M. & Lindstrom, L. H. (1996) A prospective 1–5 year outcome study in first-admitted and readmitted schizophrenic patients; relationship to heredity, premorbid adjustment, duration of disease and education level at index admission and neuroleptic treatment. Acta Psychiatrica Scandinavica, 93, 919.Google Scholar
Wright, I. C., Rabe-Hesketh, S. & Bullmore, E. T. (2000) Meta-analysis of regional brain volumes in schizophrenia. American Journal of Psychiatry, 157, 1625.CrossRefGoogle ScholarPubMed
Figure 0

Table 1 Review of magnetic resonance imaging (MRI) literature in antipsychotic-naïve patients with schizophrenia

Figure 1

Table 2 Demographic and clinical data for antipsychotic-naïve patients with schizophrenia and healthy comparison subjects

Figure 2

Table 3 Volumes (cm3) of brain regions in antipsychotic-naïve patients with schizophrenia and comparison subjects

Figure 3

Fig. 1 Third ventricle volume in antipsychotic-naïve patients with first-episode schizophrenia and healthy comparison subjects.—indicates mean third ventricle volume for the patients and controls.

Submit a response

eLetters

No eLetters have been published for this article.